You are here

Opioid-Dependence Drug Zubsolv (Buprenorphine/Naloxone) Set for U.S. Launch

Sublingual tablets approved in July (September 5)

The Swedish drug-maker Orexo has announced that Zubsolv (buprenorphine and naloxone) sublingual tablets (CIII) will be available in U.S. pharmacies from September 16. The product received FDA approval in July 2013 for the maintenance treatment of opioid dependence as part of a complete treatment plan, including counseling and psychosocial support.

According to Orexo, Zubsolv will be reimbursed in more than 70% of the current market for opioid replacement therapy. The drug will be launched with list-pricing comparable with that of Suboxone (buprenorphine and naloxone, Reckitt Benckiser) sublingual film, but with co-pay support initiatives.

Zubsolv sublingual tablets reportedly deliver more buprenorphine to the bloodstream, allowing patients to use a lower dose and thereby reducing the amount of available drug for potential misuse and diversion. The naloxone component of Zubsolv further reduces the potential for intravenous misuse and diversion.

The tablets, however, can be abused in a manner similar to other opioids, legal or illicit. Clinical monitoring appropriate to the patient’s level of stability is essential.

Adverse events commonly observed with the sublingual administration of buprenorphine/naloxone sublingual tablets during clinical trials and post-marketing experience include headache, nausea, vomiting, hyperhidrosis, constipation, signs and symptoms of withdrawal, insomnia, pain, and peripheral edema.

Source: Orexo; September 5, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs